Matrix Metalloproteinase 3 Gene Polymorphism and Its Level Predict Morbidity After Acute Myocardial Infarction.

Abstract

Matrix metalloproteinase is responsible for ventricular remodeling after acute myocardial infarction (MI). The purpose of the present study was to determine whether the matrix metalloproteinase 3 (MMP-3) polymorphism and its level predict morbidity after acute MI (AMI). We studied 112 patients with AMI and 140 controls. All patients were followed for AMI complications during their hospitalization and 6 months after. Serum MMP-3 was measured. MMP-3-1612 5A/6A polymorphism was genotyped by polymerase chain reaction. We observed that the serum MMP-3 levels were significantly increased in patients with AMI with morbidity compared with patients without complications. Also, MMP-3 levels in patients with AMI carrying 5A/5A were elevated compared with those carrying 6A/6A. The frequencies of 5A/5A genotypes were significantly increased in patients with AMI compared with controls, and patients with AMI carrying 5A/5A had a fivefold increased risk of developing morbidity. The impairment of left ventricular function (ΔFS [fractional shortening] and ΔEF [ejection fraction]) was observed more in the 5A/5A genotype compared with the 6A/6A genotype. A significant inverse correlation between predischarge MMP-3 levels and FS and EF was found at 6 months follow-up. MMP-3 polymorphism has a significant association with the risk of developing morbidity after AMI. Higher predischarge MMP-3 levels are associated with left ventricular dysfunction after AMI.